Program
Acetazolamide
Also written as “IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide”, “IHL-42X: 5 mg dronabinol + 125 mg acetazolamide” and “IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide”.
Its studies are mostly in Sleep Apnea, Obstructive · Sleep Apnea Syndromes, led by 2 companies.
Drug pageAcetazolamide: every studyAll 129 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incannex Healthcareits history only | 11 open or running | phase 2since Jun 3, 2026 | Jun 3, 2026 | Apr 2027phase 2 · NCT07635563 |
| Shionogiits history only | 11 open or running | phase 2since Jan 3, 2025 | Jan 3, 2025 | Dec 31, 2026phase 2 · NCT06776432 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 3, 2025First study: phase 2 study in Sleep Apnea SyndromesNew to ShionogiShionogi · NCT06776432 · 60 enrolled · United States
- Jun 3, 2026Incannex Healthcare’s first study: phase 2 study in Sleep Apnea, ObstructiveNew to Incannex HealthcareIncannex Healthcare · NCT07635563 · 120 planned · United States
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Sleep Apnea SyndromesShionogi · NCT06776432
- Apr 2027Primary completion: phase 2 study in Sleep Apnea, ObstructiveIncannex Healthcare · NCT07635563
TargetBeta
“Carbonic anhydrase I inhibitor; Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor; Carbonic anhydrase II inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sulthiamerule | Shionogi | phase 2 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07635563Sleep Apnea, Obstructive · United States | 2 | Recruiting | Incannex Healthcare | Apr 2027 | 120 |
| NCT06776432Sleep Apnea Syndromes · United States | 2 | Active, not recruiting | Shionogi | Dec 31, 2026 | 60 |
How it is read
Names in the registry
- “IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide”, 1 entry
- “IHL-42X: 5 mg dronabinol + 125 mg acetazolamide”, 1 entry
- “IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide”, 1 entry
- “IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide”, 1 entry
- “IHL-42X: 5 mg dronabinol + 250 mg acetazolamide”, 1 entry
Conditions, from the studies’ own filings
- Sleep Apnea, Obstructive, 1 study
- Sleep Apnea Syndromes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.